Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma
Status:
Unknown status
Trial end date:
2019-08-10
Target enrollment:
Participant gender:
Summary
Kaposi sarcoma (KS) has an unpredictable course, patients with severe KS and low CD4 counts
(<100 cells) can develop Immune Reconstitution Syndrome (IRIS) after the initiation of
combined Antiretroviral Therapy (cART). The objective of this study is to evaluate the
presence of IRIS and its attributable mortality in patients with HIV and severe KS with the
use of Ganciclovir or the prodrug Valganciclovir prior to the initiation of cART compared
with the standard management of immediate cART initiation.